In summary, these data suggest that the stem-like phenotype of GSCs can be targeted to inhibit tumor growth utilizing negative allosteric inhibitors of Grm3, although monotherapy approaches targeting Grm3 may not suffice to overcome the malignant phenotype of glioblastoma. This evidence concerns the gene GRM3 and neoplasm.